Replidyne, a developer of a new class of antibiotics in collaboration with Forest Laboratories, priced at $10, below the original proposed range of $14-$16. The company planned to offer 4.5 million shares. The stock is expected to begin trading on the NASDAQ Wednesday morning under the ticker RDYN.
